1 week Ago By ABMN Staff
Legal & General Group Plc trimmed its holdings in shares of Ocular Therapeutix, Inc. ( NASDAQ:OCUL – Free Report ) by 8.1% in the fourth quarter, according to the company in its most recent filing with the SEC.
The institutional investor owned 104,783 shares of the biopharmaceutical company’s stock after selling 9,296 shares during the quarter. Legal & General Group Plc’s holdings in Ocular Therapeutix were worth $895,000 as of its most recent filing with the SEC. A number of other large investors have also recently bought and sold shares of OCUL.
Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $43,000. AlphaQuest LLC acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $53,000.
Palumbo Wealth Management LLC acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $100,000. Cibc World Markets Corp acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $124,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Ocular Therapeutix in the 4th quarter valued at approximately $149,000.
Institutional investors and hedge funds own 59.21% of the company’s stock. Ocular Therapeutix Stock Down 2.
4 % OCUL stock opened at $7.71 on Monday. The company has a debt-to-equity ratio of 0.
19, a current ratio of 13.01 and a quick ratio of 12.94.
The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.84 and a beta of 1.
49. The business’s fifty day moving average price is $7.26 and its two-hundred day moving average price is $8.
47. Ocular Therapeutix, Inc. has a fifty-two week low of $4.
62 and a fifty-two week high of $11.78. Insider Transactions at Ocular Therapeutix In related news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th.
The shares were sold at an average price of $6.87, for a total value of $147,533.25.
Following the completion of the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. This represents a 0.
61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link . Also, insider Donald Notman sold 11,119 shares of the stock in a transaction that occurred on Tuesday, February 4th.
The shares were sold at an average price of $7.81, for a total transaction of $86,839.39.
Following the completion of the transaction, the insider now directly owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. The trade was a 5.
44 % decrease in their position. The disclosure for this sale can be found here . In the last 90 days, insiders sold 38,895 shares of company stock valued at $283,772.
Company insiders own 3.50% of the company’s stock. Analysts Set New Price Targets Several equities research analysts have recently commented on the company.
HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a report on Tuesday, March 18th.
They set an “outperform” rating and a $17.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $15.
00 price target on shares of Ocular Therapeutix in a report on Tuesday, April 8th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a report on Tuesday, March 4th.
Finally, William Blair assumed coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an “outperform” rating for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company.
Based on data from MarketBeat.com, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $16.38.
Get Our Latest Analysis on Ocular Therapeutix Ocular Therapeutix Company Profile ( Free Report ) Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. Read More Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. ( NASDAQ:OCUL – Free Report ). Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.
com's FREE daily email newsletter ..
